Coronary/Structural Heart

New Intermountain Study Aims to Determine the Most Effective Method to Identify People at Risk for Heart Disease Before They Ever Develop Problems

SALT LAKE CITY–(BUSINESS WIRE)–Researchers from the Intermountain Healthcare Heart Institute are launching one of the largest and most ambitious research initiatives ever undertaken in the state of Utah to test a new standard of care to better identify and treat people at risk of having a heart attack – and […]

Toyoda Gosei and EBM Corp. Launch “SupeR BEAT” Medical Simulator Using e-Rubber

KIYOSU, Japan–(BUSINESS WIRE)–Toyoda Gosei Co., Ltd. (TOKYO: 7282) and EBM Corporation1 today launched the “SupeR BEAT” surgical training simulator. This simulator can reproduce the beating of the heart with extreme accuracy using e-Rubber, an innovative material that moves with electricity. The two companies have been collaborating since November 2017 to develop […]

CORRECTING and REPLACING CAPTION FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

CORRECTION…by Abiomed October 26, 2019 09:15 AM Eastern Daylight Time DETROIT–(BUSINESS WIRE)–Please replace the caption for release dated October 25, 2019 with the accompanying corrected caption. The release reads: FDA POST APPROVAL STUDY DEMONSTRATES TIMELY IDENTIFICATION OF RIGHT HEART FAILURE AND EARLY USE OF IMPELLA RP LEADS TO HIGHER SURVIVAL […]

FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI™ (COF-fee) System

BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the FDA has designated the company’s CoFI (CorFlow Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI™ System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents […]

Heart MRI Delivers Accurate Diagnosis and Helps Guide Treatment of Cardiovascular Diseases

MOUNT ROYAL, N.J., Oct. 22, 2019 /PRNewswire/ — A recent study published in the New England Journal of Medicine supports the use of heart magnetic resonance imaging (Heart MRI) for improved diagnosis and treatment of patients with chest pain. Heart MRI is a non-invasive method for providing a complete visual evaluation of the anatomy and […]

MedHub’s AI-powered Solutions Are Disrupting Cardiology

The software company is commencing its pivotal multi-center clinical trial, aimed at demonstrating the efficacy of its ground-breaking product – AutocathFFR TEL AVIV, Israel, Oct. 22, 2019 /PRNewswire/ — MedHub develops decision-support systems for cardiologists that leverage Artificial Intelligence (AI) to guide cardiologists during the diagnostic cardiac angiography process. The fully automated […]

Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate

WINNIPEG, Oct. 15, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America (“HFSA”) conference in Philadelphia, PA by Dr. William T. Abraham, the […]

Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation

VANCOUVER, Oct. 15, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the United States Patent […]

CHF Solutions Announces that James A. Haley Veterans’ Hospital Receives Final Approval To Initiate Heart Failure Outpatient Study utilizing Aquadex FlexFlow® System

First Study of Aquadex FlexFlow System Sponsored by United States Veterans Administration for Aquapheresis Treatment in Patients Suffering from Fluid Overload. First patient enrollment expected in the fourth quarter of 2019. EDEN PRAIRIE, Minn., Oct. 10, 2019 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), today announced that James A. Haley […]

PENUMBRA ANNOUNCES FIRST PATIENT ENROLLED IN STUDY OF MECHANICAL POWER ASPIRATION FOR THROMBUS REMOVAL IN CORONARY VESSELS

Prospective Study to Evaluate Safety and Performance of Indigo® System and CAT RX Aspiration Catheter ALAMEDA, Calif. – October 10, 2019 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S. study to […]